5 completed, 5 recruiting, 2 active not recruiting, 2 not yet recruiting. 17 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 5, Recruiting 5, Active not recruiting 2, Not yet recruiting 2, Enrolling by invitation 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 3 | Recruiting 2, Completed 1 |
Follow SPECT: new trials by email Literature Review of SPECT trials Research Report on SPECT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-12-01 | 2026-10-15 |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab - Refractory Myelodysplastic Syndrome | Phase 1 | Suspended | National Cancer Institute (NCI) | 18 | 2026-09-03 | 2026-09-09 |
| Molecular Imaging of EpCam Expression in Breast Cancer Using [99mTc]Tc-DARPinEc1-G3C [99mTc]Tc-DARPinEc1-G3C - Primary Breast Cancer | Phase 1 | Enrolling by invitation | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2026-06-22 | 2026-08-26 |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-07-01 | 2026-10-30 |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial Angiogram, Biospecimen Collection, Computed Tomography - Stage I Renal Cell Cancer, Stage II Renal Cell Cancer | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 25 | 2024-12-26 | 2026-08-21 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
| Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma | Phase 1 | Active not recruiting | Emory University | 6 | 2023-11-29 | 2025-12-09 |
| Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 SPECT - Primary Breast Cancer | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2023-09-01 | 2026-06-24 |
| Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2 SPECT - Breast Cancer Female | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 30 | 2021-12-22 | 2026-06-26 |
| Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 SPECT - Primary Breast Cancer | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 30 | 2020-02-10 | 2026-06-24 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 | Phase 1 | Completed | Mayo Clinic | 9 | 2017-03-22 | 2024-09-27 |
| Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer Angiography, Computed Tomography, Planar Imaging - Metastatic Liver Carcinoma, Stage IV Liver Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 12 | 2017-01-09 | 2026-09-16 |
| Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 / Phase 2 | Completed | Mayo Clinic | 38 | 2004-10-01 | 2016-02-04 |
Breast Neoplasms (4) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Mycosis Fungoides (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Prostatic Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Gliosarcoma (1) · Immunoblastic Lymphadenopathy (1)
Mayo Clinic (4) · Tomsk National Research Medical Center of the Russian Academy of Sciences (4) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · University of Michigan Rogel Cancer Center (1)
United States (11) · Russia (4)
Armeen Mahvash (1) · Brenda M. Sandmaier (1) · David M Schuster, MD, FACR (1) · Dusica Babovic-Vuksanovic, MD (1) · Jeffrey Y Wong (1) · Joselle Cook, M.B.B.S. (1) · Kah Whye Peng, PhD (1) · Kirk A Frey, MD (1) · Megan Mantica (1) · Nora Bennani, M.D. (1) · Nora Bennani, MD (1) · Olga Bragina, Dsc (1) · Siddharth A Padia (1) · Talha Badar (1) · Thomas Witzig (1)
PMID 35175355, PMID 30335787, PMID 33641042, PMID 34385343, PMID 36898933, PMID 38407630, PMID 41276366
P50CA186781 (2), R01CA262613 (2), P01CA078902 (1), P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA138292 (1), R01CA289631 (1), UM1CA186690 (1), UM1CA186709 (1), UM1CA186712 (1)